Portal de investigación
Predicción de enfermedad residual después de la terapia neoadyuvante en cáncer de mama HER2 positivo e identificación de estrategias para superar la resistencia.
Datos básicos
Documentos
- No hay documentos
Participantes
Grupos y Plataformas de I+D+i
Financiadores - Promotores
INSTITUTO SALUD CARLOS III
INSTITUTO SALUD CARLOS III
Resultados del Ensayo Clínico
High VEGFR3 Expression Reduces Doxorubicin Efficacy in Triple-Negative Breast Cancer
Torres-Ruiz, Sandra; (...); Eroles, Pilar
Article. 10.3390/ijms24043601. 2023
Involvement of microRNAs-449/FASN axis in response to trastuzumab therapy in HER2-positive breast cancer
Lameirinhas, A; (...); Eroles, P
Article. 10.1186/s10020-025-01163-z. 2025
MicroRNAs as a clue to overcome breast cancer treatment resistance.
Garrido-Cano, Iris; (...); Eroles, Pilar
Article. 10.1007/s10555-021-09992-0. 2022
miR-146a-5p Promotes Angiogenesis and Confers Trastuzumab Resistance in HER2+Breast Cancer
Cabello, Paula; (...); Eroles, Pilar
Article. 10.3390/cancers15072138. 2023
MiRNA-449 family is epigenetically repressed and sensitizes to doxorubicin through ACSL4 downregulation in triple-negative breast cancer
Torres-Ruiz, S; (...); Eroles, P
Article. 10.1038/s41420-024-02128-7. 2024
Synthesis of 2-aminopropyl benzopyran derivatives as potential agents against triple-negative breast cancer
García, A; (...); Cortes, D
Article. 10.1039/d3md00385j. 2023
